This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Grapefruit juice (drug interactions)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Cyclosporin, terfenadine and most calcium channel blockers should not be taken with grapefruit juice. This is because grapefruit juice inhibits the metabolism of certain drugs by enzymes of subfamily cytochrome P45 (CYP 3A4 (2)). The effect reduces the metabolism of terfenadine, cyclosporin, and calicum channel blockers (other than amlodipine and diltiazem).

Statins and grapefruit juice

  • simvastatin and grapefruit juice - pharmacokinetic evidence suggests that grapefruit juice should be avoided altogether, as even modest quantities of this drink can significantly increase exposure to simvastatin (3)
  • for atorvastatin - patients should also avoid drinking large quantities of grapefruit juice (3)

Reference:

  1. Current Problems in Pharmacovigilance (1997); 23:2.
  2. Walter-Sack I, Klotz U (1996). Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinetics, 31, 47-64.
  3. Current Problems in Pharmacovigilance (2004); 30: 1-12.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.